Skip to main content

Advertisement

Table 2 Treatment and chemotherapeutic regimens (n = 41)

From: Desmoplastic small round cell tumour: characteristics and prognostic factors of 41 patients and review of the literature

Variables No. of patients (%)
Treatment modality  
Chemotherapy 38 (93%)
   - Neoadjuvant 4 (10%)
   - Adjuvant 2 (5%)
   - Palliative (including relapse after neoadjuvant/ adjuvant treatment) 35 (85%)
Radiotherapy  
   - Radical 2 (5%)
   - Palliative 4 (10%)
Surgery and its indications  
   - Diagnosis 14 (34%)
   - Resection/optimal debulking of primary tumour 8 (20%)
Chemotherapy  
First-line  
   - Vincristine + ifosfamide + doxorubicin + etoposide (VIDE) 13
   - Ifosfamide + vincristine + actinomycin D + doxorubicin (IVADo) 7
   - Cyclophosphamide or ifosfamide + etoposide 4
   - Vincristine + doxorubicin + cyclophosphamide (VAC) or vincristine + ifosfamide + doxorubicin 4
   - Bleomycin + etoposide + cisplatin 2
   - Ifosfamide + doxorubicin 2
   - Carboplatin + etoposide 1
   - Carboplatin + paclitaxel 1
   - Cisplatin + doxorubicin/paclitaxel + cisplatin + ifosfamide 1
   - Doxorubicin 1
   - Epirubicin + cisplatin + capecitabine 1
   - Ifosfamide + carboplatin + etoposide 1
   - Ifosfamide + vincristine + actinomycin D 1
Subsequent-line (with chemotherapeutic agents)  
   - Platinum + etoposide 10
   - Etoposide 5
   - Ifosfamide + etoposide 5
   - Doxorubicin 2
   - Ifosfamide + doxorubicin 2
   - Cyclophosphamide + topotecan 2
   - VAC 2
   - Gemcitabine or irinotecan + temozolomide 2
   - Albumin-bound paclitaxel 1
   - Cisplatin + mitomycin C + irinotecan 1
   - Doxorubicin + etoposide 1
   - IVADo 1
   - Liposomal doxorubicin 1
   - VIDE 1
Subsequent-line (with non-standard therapies)  
   - Figitumumab 2
   - Sirolimus + cyclophosphamide or liposomal doxorubicin 2
   - Pazopanib +/− etoposide 2
   - Sunitinib 2
   - Axitinib 1
   - Goserelin 1
   - Interferon 1
   - Semaxanib 1
   - Sorafenib 1